Clinical Trial: A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

U.S., May 3 -- ClinicalTrials.gov registry received information related to the study (NCT06954961) titled 'A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer' on Dec. 20, 2024.

Brief Summary: This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.

Study Start Date: Sept. 15, 2022

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: D-0502

* Dosage form: Tablet

* Administration route: Oral, once a day

DRUG: Fulvestrant

* Dosage form: Injection

* ...